UAE approves Rinvoq for vitiligo patients aged 12+, creating first country-level oral licence

The United Arab Emirates has become the first country to approve Rinvoq (upadacitinib) as a once-daily oral treatment for non-segmental vitiligo in adults and adolescents aged 12 years and older who require systemic therapy.

The highest-stakes readers are dermatology operators, insurers and medical directors. Dubai clinics licensed by the Dubai Health Authority (DHA) will need protocols for patient selection, consent and monitoring. Abu Dhabi providers regulated by the Department of Health Abu Dhabi (DOH) will need to map the indication into payer approval workflows. Providers in Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah will need to follow Ministry of Health and Prevention (MOHAP) facility and pharmacy rules while the federal drug approval sits with the Emirates Drug Establishment (EDE).

What EDE approved

Arabian Business reported the approval on 17 August 2026. The primary announcement from WAM said EDE approved a new therapeutic indication for Rinvoq to treat non-segmental vitiligo in patients aged 12 and above whose condition requires medicines that circulate through the bloodstream.

Rinvoq is an oral Janus kinase inhibitor made by AbbVie. The vitiligo indication uses 15 mg once daily, according to AbbVie’s European Commission approval announcement on 29 July 2026. That European decision covered adults and adolescents aged 12 years and older who are candidates for systemic therapy. EDE has framed the UAE decision as the first country-level approval for this oral use.

AbbVie said the European approval was supported by two replicate Phase 3 Viti-Up studies under protocol M19-044. The trials measured T-VASI 50, a 50% reduction in total-body vitiligo severity, and F-VASI 75, a 75% reduction in facial vitiligo severity, at week 48 versus placebo. That 48-week horizon matters for clinics because patient counselling and payer reviews should be built around months of treatment, rather than a short cosmetic procedure cycle.

What clinics and insurers should price

The approval does not settle reimbursement. UAE insurers will assess Rinvoq under policy wording, network rules and prior-authorisation criteria. In Abu Dhabi, that means particular attention to Daman and Thiqa pathways where applicable. In Dubai and the wider UAE private market, payers such as Sukoon may require documentation that the patient has non-segmental vitiligo and meets systemic-therapy criteria.

The practical checklist for dermatology clinics is short:

• Confirm the diagnosis is non-segmental vitiligo, not segmental disease.
• Record age, disease extent, facial involvement and prior topical or phototherapy use.
• Check the approved UAE product information before prescribing to adolescents aged 12 to 17.
• Submit payer requests with severity scores and the reason systemic therapy is required.

Local cost is the unresolved commercial point. A UAE retail listing for Rinvoq 15 mg, 30 tablets on Life Pharmacy showed AED 5,789 inclusive of VAT, marked out of stock, for existing Rinvoq supply. That is a market reference, not an official reimbursement tariff for vitiligo. CFOs should verify the current registered medicine price through the MOHAP price list service or pharmacy procurement channel before forecasting monthly drug cost.

Why it matters in Dubai first

Dubai has a large private dermatology and aesthetics market, and vitiligo patients often enter care through cosmetic dermatology rather than hospital immunology. The new indication shifts part of that demand toward medical dermatology follow-up, laboratory monitoring and insurer authorisation. Clinics that rely on cash-pay aesthetic visits will need a separate pathway for chronic autoimmune care.

Medical directors should treat the approval as a governance issue. Rinvoq is an immunomodulating medicine. Patient selection should be documented, adverse-event counselling should be standardised and prescribing should sit with clinicians who can monitor systemic therapy. The EDE announcement also advised patients who notice unusual skin-colour changes to consult a specialist for early diagnosis and proper assessment.

For patients, the change is access to an oral option where topical treatment, phototherapy or watchful waiting is insufficient. For operators, the change is administrative. The winning clinics will be those that can prove eligibility, secure payer approval and manage follow-up over a 48-week treatment horizon. Patients and referrers can use the UAE Open Healthcare Directory to find licensed dermatology providers across Dubai, Abu Dhabi and the northern emirates.